HQ: Budapest, Hungary
Countries we work from: Hungary, United Kingdom, Spain, The Netherlands, United States of America, Italy, Poland, Belgium, Austria, Germany
Team size: 80+
Founders: Nagy Szabolcs (CEO), Dr. Veres Dániel (CSO), Szalay Kristóf (CTO), Dr. Fekete Iván (Lead Application Scientist)
Founding date: 2016
Notable investors: Accel, Mercia Asset Management, XTX Ventures, Delin Ventures, Interactive Venture Partners, MassMutual Ventures, MSD Global Health and Innovation Fund, Accenture and others
Investment Stage: Series B
Funding to date: $60M+
A lab without limits, built for biopharma. Turbine’s Virtual Lab digitizes biology, letting scientists run millions of virtual experiments at a scale no traditional lab can match. Instead of narrowing a hypothesis to fit resource constraints, teams use Turbine’s Virtual Assays, built on Turbine’s Virtual Cell model, to predict lab-like outputs, from cellular phenotypes to molecular states, across millions of conditions in parallel. Turbine doesn’t replace the wet lab. It makes every experiment count. Through a seamless Lab-in-the-Loop workflow, virtual findings become testable conditions, validated in-house, with a CRO partner, or through Turbine’s own lab, with results feeding back to sharpen every future prediction. The impact: decisions that once took 12 to 18 months now take as little as 2 months of in silico analysis, with over 50% wet lab experiments saved along the way.
Please use these assets as provided or follow the included brand guidelines for any adaptations.
If you have any questions for our communications team, or would like to request an interview, data, or comment, contact us here.